CentrosHealth will now Capture Medical Device Data
According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis.
Clinical Ink, a provider of eSource solutions for clinical trials, announced that CentrosHealth, a mobile patient engagement platform, now includes streamlined connectivity for a wide range of medical devices. This new platform was developed with cooperation from Novartis and PPD, who are also supporting a pilot clinical study before broad commercial use. According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis. Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
